Prospective Multicenter Observational Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic Non-small Cell Lung Cancer: (J-TAIL)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms J-TAIL
- Sponsors Chugai Pharmaceutical
- 24 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2019 Planned End Date changed from 1 Apr 2023 to 1 Apr 2022.
- 03 Oct 2019 Planned primary completion date changed from 1 Dec 2022 to 31 Oct 2019.